FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313646726> ?p ?o ?g. }

• W4313646726 endingPage "369" @default.
• W4313646726 startingPage "367" @default.
• W4313646726 abstract "As the mass vaccination strategies had been carried, cutaneous adverse reactions to COVID-19 vaccines have been progressively reported. But previous studies were mainly about mRNA vaccines and the cutaneous reactions of Chinese people to the CoronaVac or ZF2001 vaccines were rarely reported. In this letter, we report a case series of 61 patients who developed cutaneous reaction after CoronaVac or ZF2001 COVID-19 vaccination from a single center between May 1 and November 30, 2021. The age of 61 patients ranged from 18 to 71 years, and the median age was 30 (23–41.5) years. Out of the 61 patients, who were all yellow race, the vast majority (62.3%) were females (Table S1). About half of the patients (50.8%) were healthy (Table S2), and the rest reported suffering from allergic or chronic diseases without significant difference between females and males. There were 6 patients lost to follow-up, and 55 patients completed the follow-up. Of the 55 patients, 10 suspended their vaccination course due to concerns about the skin side effects, including 5 patients injected only one dose and 5 patients injected two doses. Actually, expect the 5 patients just mentioned, there are another 12 injected two doses, because it is not yet the time that they should injected the third dose when we called them at the last time. Forty-four patients developed cutaneous reactions only once, and only 11 patients suffered cutaneous reactions twice or thrice. (Figure S1B). A broad spectrum of reactions after vaccination were observed. The local reactions were most common, followed by urticarial eruptions, morbilliform rash, psoriatic lesions, herpes, pityriasis rosea-like reactions, acne-like reactions, dermatomyositis, and atopic dermatitis. (Figure S2). All patients' conditions were improved after receiving the traditional treatment, including antihistamine, antiviral, glucocorticoid, glycyrrhizin, and Chinese patent medicine. Otherwise, one urticaria case and two worsening psoriasis cases received biologics to treat. In our study, alopecia areata was not observed, while others reported alopecia areata following SARS-CoV-2 vaccination.1 It is worth noting that there are significant differences in types of cutaneous reactions and duration time between males and females (Table 1 and Table 2). Females (68.4%) are more likely to suffer local reactions compared to males (17.4%), while males (17.4%) were significantly more affected by psoriasis than females (0%). Besides, the cutaneous reactions of males are more diverse. The females only reported five kinds of reactions while males reported nine kinds. In our report, males (36.4%) were more likely to experience initial cutaneous reactions to the third dose, compared to females (4.5%). A majority (74.6%) of patients experienced cutaneous symptoms within 3 days, with no significant difference across gender groups in terms of reaction time. With regard to duration time, females (60.6%) were more likely to resolve within 7 days compared to males (27.3%). All nine patients reported chronic course were males, who experienced urticaria, psoriasis, dermatomyositis, or atopic dermatitis over 3 months (Figure S1C). The gender difference of cutaneous reactions after COVID-19 vaccination has also been noted by other scholars. In a multicenter study involving 2097 individuals received the CoronaVac vaccine conducted in Turkey, systemic reactions and local injection site reactions were statistically significantly higher in women.2 This gender-related difference may relate to be that men and women differ in their innate, humoral, and cell-mediated responses to viral vaccines.3 The most frequently reported patterns in each vaccine group were local reaction (ZF2001, 69.0%) and morbilliform (CoronaVac, 31.6%). Out of 61 patients, the most common reaction is local reaction, which also named COVID-ARM.4 Compared with results of others,5 our patients (86.7%) occurred local reaction more quickly (3 days) (Figure S1C,D). Morbilliform rash is regarded as the initial manifestation of COVID-196; Morbilliform reaction after injecting CoronaVac (inactivated vaccines) seems to resemble COVID-19 skin manifestations.7 By contrast, local reaction seems an allergic reaction. So, we speculate the types of vaccines maybe the reason of different reactions (Table 2). In summary, the most common cutaneous reaction in our study was local reaction, which is also the most common in females and ZF2001 group. Urticaria rash was most frequently reported in males, and morbilliform rash was the most common in CoronaVac group. Totally, most cutaneous reactions after vaccination are mild, and a large proportion of patients could resolve through conventional therapy within 7–14 days. This study may help physicians to provide relevant advice for vaccine counseling and to treat cutaneous reactions. Qian Li, Qing Li, and Y.L. designed this research. Qing Li and Y.S. did the work of literature search. Qing Li and Qian Li performed the research. Qing Li, Qian Li, Y.S, S.S., H.H, L.L., and Y.M. did the work of data acquisition. Qing Li, Qian Li, S.S., and Y.L. analyzed the data. Qing Li wrote the paper. Qian Li and Y.L. revised and polished the paper. All authors have read and approved the final manuscript. None. No potential conflict of interest was reported by the author. The patients in this manuscript have given oral informed consent to the publication of their case details. Ethical approval of the study was granted by the Hebei Medical University Third Affiliated Hospital Research Ethics Committee (2022-012-1). Appendix S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W4313646726 created "2023-01-07" @default.
• W4313646726 creator A5014243236 @default.
• W4313646726 creator A5014942240 @default.
• W4313646726 creator A5026253671 @default.
• W4313646726 creator A5037641781 @default.
• W4313646726 creator A5039984043 @default.
• W4313646726 creator A5043968617 @default.
• W4313646726 creator A5053780153 @default.
• W4313646726 creator A5075950166 @default.
• W4313646726 date "2023-01-06" @default.
• W4313646726 modified "2023-09-25" @default.
• W4313646726 title "Cutaneous reactions after <scp>COVID</scp>‐19 vaccination: A single‐center retrospective study in China with 61 cases" @default.
• W4313646726 cites W2131643987 @default.
• W4313646726 cites W3044985759 @default.
• W4313646726 cites W3150660033 @default.
• W4313646726 cites W3157377181 @default.
• W4313646726 cites W3212228033 @default.
• W4313646726 cites W4283593183 @default.
• W4313646726 cites W4283790721 @default.
• W4313646726 doi "https://doi.org/10.1111/jocd.15586" @default.
• W4313646726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36606402" @default.
• W4313646726 hasPublicationYear "2023" @default.
• W4313646726 type Work @default.
• W4313646726 citedByCount "1" @default.
• W4313646726 countsByYear W43136467262023 @default.
• W4313646726 crossrefType "journal-article" @default.
• W4313646726 hasAuthorship W4313646726A5014243236 @default.
• W4313646726 hasAuthorship W4313646726A5014942240 @default.
• W4313646726 hasAuthorship W4313646726A5026253671 @default.
• W4313646726 hasAuthorship W4313646726A5037641781 @default.
• W4313646726 hasAuthorship W4313646726A5039984043 @default.
• W4313646726 hasAuthorship W4313646726A5043968617 @default.
• W4313646726 hasAuthorship W4313646726A5053780153 @default.
• W4313646726 hasAuthorship W4313646726A5075950166 @default.
• W4313646726 hasBestOaLocation W43136467261 @default.
• W4313646726 hasConcept C126322002 @default.
• W4313646726 hasConcept C141071460 @default.
• W4313646726 hasConcept C16005928 @default.
• W4313646726 hasConcept C167135981 @default.
• W4313646726 hasConcept C185592680 @default.
• W4313646726 hasConcept C197934379 @default.
• W4313646726 hasConcept C203014093 @default.
• W4313646726 hasConcept C21951064 @default.
• W4313646726 hasConcept C22070199 @default.
• W4313646726 hasConcept C2779134260 @default.
• W4313646726 hasConcept C2991831687 @default.
• W4313646726 hasConcept C2994436531 @default.
• W4313646726 hasConcept C3008058167 @default.
• W4313646726 hasConcept C3020442560 @default.
• W4313646726 hasConcept C524204448 @default.
• W4313646726 hasConcept C71924100 @default.
• W4313646726 hasConceptScore W4313646726C126322002 @default.
• W4313646726 hasConceptScore W4313646726C141071460 @default.
• W4313646726 hasConceptScore W4313646726C16005928 @default.
• W4313646726 hasConceptScore W4313646726C167135981 @default.
• W4313646726 hasConceptScore W4313646726C185592680 @default.
• W4313646726 hasConceptScore W4313646726C197934379 @default.
• W4313646726 hasConceptScore W4313646726C203014093 @default.
• W4313646726 hasConceptScore W4313646726C21951064 @default.
• W4313646726 hasConceptScore W4313646726C22070199 @default.
• W4313646726 hasConceptScore W4313646726C2779134260 @default.
• W4313646726 hasConceptScore W4313646726C2991831687 @default.
• W4313646726 hasConceptScore W4313646726C2994436531 @default.
• W4313646726 hasConceptScore W4313646726C3008058167 @default.
• W4313646726 hasConceptScore W4313646726C3020442560 @default.
• W4313646726 hasConceptScore W4313646726C524204448 @default.
• W4313646726 hasConceptScore W4313646726C71924100 @default.
• W4313646726 hasIssue "2" @default.
• W4313646726 hasLocation W43136467261 @default.
• W4313646726 hasLocation W43136467262 @default.
• W4313646726 hasOpenAccess W4313646726 @default.
• W4313646726 hasPrimaryLocation W43136467261 @default.
• W4313646726 hasRelatedWork W2003938723 @default.
• W4313646726 hasRelatedWork W2047967234 @default.
• W4313646726 hasRelatedWork W2118496982 @default.
• W4313646726 hasRelatedWork W2364998975 @default.
• W4313646726 hasRelatedWork W2369162477 @default.
• W4313646726 hasRelatedWork W2439875401 @default.
• W4313646726 hasRelatedWork W2465057261 @default.
• W4313646726 hasRelatedWork W4220720399 @default.
• W4313646726 hasRelatedWork W4238867864 @default.
• W4313646726 hasRelatedWork W2525756941 @default.
• W4313646726 hasVolume "22" @default.
• W4313646726 isParatext "false" @default.
• W4313646726 isRetracted "false" @default.
• W4313646726 workType "article" @default.